Start-Up Quarterly Statistics, Q4 2009
This article was originally published in Start Up
Highlights from the Q4 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $976 million, an 88% increase from the previous quarter, and a 77% jump from Q4 2008's $551 million. Of the total fundraising, 66% or $640 million went to the biopharma industry. Compared with Q3 2009, device fundraising rose by 85% (from $113 million to $209 million) and diagnostics companies raised 72% more (from $74 million to $127 million). The fourth quarter of 2009 saw eight acquisitions, all of them in the biopharma industry. Big Pharmas were busy signing deals with start-ups--Sanofi-Aventis inked three while Roche and Novartis AG each signed two.
You may also be interested in...
New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. In biopharmaceuticals, corporate venture got in at the ground floor while device start-ups continued to see stronger support from smaller, regional investors than traditional VCs.
Formed by the 2009 merger of CELLective DX and DNA Repair Co., On-Q-ity Inc. is developing personalized molecular diagnostics for cancer. The start-up thinks that combining DNA repair biomarkers with its ability to capture and analyze circulating tumor cells provides a complete view of an individual patient's pending treatment options and allows for more patient-friendly monitoring of the treatment's progress. On-Q-ity is currently conducting large-scale trials analyzing the response of DNA repair mechanisms to breast cancer therapies, focusing particularly on the anthracycline class of drugs. Initial studies are based on tissue samples, but the company will begin trials with circulating tumor cells in various cancers later this year.
Big Pharma, unable to exploit its own research productivity, is increasingly seeing itself as a supplier of discovery assets. That's bad news for discovery-based biotech, but good news for companies with a talent for faster, more predictable development capabilities. Since its formation in the fall of 2007, Flexion Therapeutics has apparently had no trouble getting Big Pharmas to let them review their shelved compounds, 130 or so of them from eight to 10 companies. Flexion, built around Lilly's fast-to-proof-of-concept strategy, is attempting to take advantage of the trend; it's in-licensed five products from three Big Pharmas.